论文部分内容阅读
美国国立卫生研究院(NIH)下属的国立癌症研究所(NCI)已在全美6家中心启动一项为期2年的验证发现早期肝癌试验的研究项目;该试验由NCI的早期诊断研究网络(EDRN)协助策划,通过试验可观察到一种被称作去γ羟基凝血酶原(DCP)的物质可以鉴别肝癌的危险性。确证——证实一种物质精确表示癌存在风险的
The National Institutes of Health (NIH), a subsidiary of the National Institutes of Health, has started a two-year validation study of early-stage hepatocellular carcinoma at six centers nationwide; the trial was conducted by NCI’s Early Diagnostic Research Network (EDRN ) To assist in the planning of a test for the presence of a substance called dehydroxygen prothrombin (DCP) that identifies the risk of liver cancer. Confirmation - Confirmation of a substance that is at risk for cancer